Inhibition of hepatitis C virus in chimeric mice by short synthetic hairpin RNAs: Sequence analysis of surviving virus shows added selective pressure of combination therapy

Journal of Virology

Volumn 88, Issue 9, 2014, Pages 4647-4656

  Dallas, Anne ^a   Ilves, Heini ^a   Ma, Han ^b   Chin, Daniel J ^b   MacLachlan, Ian ^c   Klumpp, Klaus ^b   Johnston, Brian H ^a  

^a SomaGenics Inc   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c Tekmira Pharmaceuticals Corporation   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; LUCIFERASE; SG220; SG221C; SG273; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHIMERA; CONTROLLED STUDY; DRUG EFFICACY; GENE TARGETING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; RNA DEGRADATION; RNA INTERFERENCE; RNA SEQUENCE; SEQUENCE ANALYSIS; VIRUS CHARACTERIZATION; VIRUS GENOME; VIRUS INHIBITION; VIRUS LOAD; VIRUS RESISTANCE;

ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; HEPACIVIRUS; HEPATITIS C; MALE; MICE; MUTATION; RNA, SMALL INTERFERING; SELECTION, GENETIC; SEQUENCE ANALYSIS;

EID: 84897510065     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00105-14     Document Type: Article

References (69)

1. Clark PJ, Muir AJ. 2012. Overcoming barriers to care for hepatitis C. N. Engl. J. Med. 366:2436-2438. http://dx.doi.org/10.1056/NEJMp1202608.
2. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. 2013. Hepatitis C in the United States. N. Engl. J. Med. 368:1859-1861. http://dx.doi.org/10.1056/NEJMp1302973.
3. Farci P. 2011. New insights into the HCV quasispecies and compartmentalization. Semin. Liver Dis. 31:356-374. http://dx.doi.org/10.1055/s-0031-1297925.
4. Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R, Guardia J, Gomez J. 1992. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature ofHCVgenome distribution. J. Virol. 66:3225-3229.
5. Powdrill MH, Tchesnokov EP, Kozak RA, Russell RS, Martin R, Svarovskaia ES, Mo H, Kouyos RD, Gotte M. 2011. Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proc. Natl. Acad. Sci. U. S. A. 108:20509-20513. http://dx.doi.org/10.1073/pnas.1105797108.
6. Sun JH, O'Boyle DR, II, Zhang Y, Wang C, Nower P, Valera L, Roberts S, Nettles RE, Fridell RA, Gao M. 2012. Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052. Hepatology 55:1692-1699. http://dx.doi.org/10.1002/hep.25581.
7. Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, McPhee F, Hughes E, Kumada H. 2012. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 55:742-748. http://dx.doi.org/10.1002/hep.24724.
8. Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, Ipe D, Morcos PN, Baher L, Najera I, Chu T, Lopatin U, Berrey MM, Bradford W, Laughlin M, Shulman NS, Smith PF. 2010. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376:1467-1475. http://dx.doi.org/10.1016/S0140-6736(10)61384-0.
9. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C. 2012. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366:216-224. http://dx.doi.org/10.1056/NEJMoa1104430.
10. Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, Moreno C, Zarski JP, Horsmans Y, Mo H, Arterburn S, Knox S, Oldach D, McHutchison JG, Manns MP, Foster GR. 2012. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 55:749-758. http://dx.doi.org/10.1002/hep.24744.
11. Pestova TV, Shatsky IN, Fletcher SP, Jackson RJ, Hellen CU. 1998. A prokaryotic-like mode of cytoplasmic eukaryotic ribosome binding to the initiation codon during internal translation initiation of hepatitis C and classical swine fever virus RNAs. Genes Dev. 12:67-83. http://dx.doi.org/10.1101/gad.12.1.67.
12. Bukh J, Miller RH, Purcell RH. 1995. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin. Liver Dis. 15:41-63. http://dx.doi.org/10.1055/s-2007-1007262.
13. Simmonds P. 2004. Genetic diversity and evolution of hepatitis C virus-15 years on. J. Gen. Virol. 85:3173-3188. http://dx.doi.org/10.1099/vir.0.80401-0.
14. Barros SA, Gollob JA. 2012. Safety profile of RNAi nanomedicines. Adv. Drug Deliv. Rev. 64:1730-1737. http://dx.doi.org/10.1016/j.addr.2012.06.007.
15. Sehgal A, Vaishnaw A, Fitzgerald K. 2013. Liver as a target for oligonucleotide therapeutics. J. Hepatol. 59:1354-1359. http://dx.doi.org/10.1016/j.jhep.2013.05.045.
16. Wilson JA, Jayasena S, Khvorova A, Sabatinos S, Rodrigue-Gervais IG, Arya S, Sarangi F, Harris-Brandts M, Beaulieu S, Richardson CD. 2003. RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proc. Natl. Acad. Sci. U. S. A. 100:2783-2788. http://dx.doi.org/10.1073/pnas.252758799.
17. Yokota T, Sakamoto N, Enomoto N, Tanabe Y, Miyagishi M, Maekawa S, Yi L, Kurosaki M, Taira K, Watanabe M, Mizusawa H. 2003. Inhibition of intracellular hepatitis C virus replication by synthetic and vectorderived small interfering RNAs. EMBO Rep. 4:602-608. http://dx.doi.org/10.1038/sj.embor.embor840.
18. Seo MY, Abrignani S, Houghton M, Han JH. 2003. Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7. J. Virol. 77:810-812. http://dx.doi.org/10.1128/JVI.77.1.810-812.2003.
19. Kanda T, Steele R, Ray R, Ray RB. 2007. Small interfering RNA targeted to hepatitis C virus 5' nontranslated region exerts potent antiviral effect. J. Virol. 81:669-676. http://dx.doi.org/10.1128/JVI.01496-06.
20. Randall G, Panis M, Cooper JD, Tellinghuisen TL, Sukhodolets KE, Pfeffer S, Landthaler M, Landgraf P, Kan S, Lindenbach BD, Chien M, Weir DB, Russo JJ, Ju J, Brownstein MJ, Sheridan R, Sander C, Zavolan M, Tuschl T, Rice CM. 2007. Cellular cofactors affecting hepatitis C virus infection and replication. Proc. Natl. Acad. Sci. U. S. A. 104:12884-12889. http://dx.doi.org/10.1073/pnas.0704894104.
21. Kronke J, Kittler R, Buchholz F, Windisch MP, Pietschmann T, Bartenschlager R, Frese M. 2004. Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs. J. Virol. 78: 3436-3446. http://dx.doi.org/10.1128/JVI.78.7.3436-3446.2004.
22. Ma H, Dallas A, Ilves H, Shorenstein J, Maclachlan I, Klumpp K, Johnston BH. 2013. Formulated minimal-length synthetic small hairpin RNAs are potent inhibitors of hepatitis C virus in mice with humanized livers. Gastroenterology 146:63-66.e5. http://dx.doi.org/10.1053/j.gastro.2013.09.049.
23. Vlassov AV, Korba B, Farrar K, Mukerjee S, Seyhan AA, Ilves H, Kaspar RL, Leake D, Kazakov SA, Johnston BH. 2007. shRNAs targeting hepatitis C: effects of sequence and structural features, and comparison with siRNA. Oligonucleotides 17:223-236. http://dx.doi.org/10.1089/oli.2006.0069.
24. Ge Q, Dallas A, Ilves H, Shorenstein J, Behlke MA, Johnston BH. 2010. Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs. RNA 16:118-130. http://dx.doi.org/10.1261/rna.1901810.
25. Ge Q, Ilves H, Dallas A, Kumar P, Shorenstein J, Kazakov SA, Johnston BH. 2010. Minimal-length short hairpin RNAs: the relationship of structure and RNAi activity. RNA 16:106-117. http://dx.doi.org/10.1261/rna.1894510.
26. Wang Q, Contag CH, Ilves H, Johnston BH, Kaspar RL. 2005. Small hairpin RNAs efficiently inhibit hepatitis C IRES-mediated gene expression in human tissue culture cells and a mouse model. Mol. Ther. 12:562-568. http://dx.doi.org/10.1016/j.ymthe.2005.04.014.
27. Ilves H, Kaspar RL, Wang Q, Seyhan AA, Vlassov AV, Contag CH, Leake D, Johnston BH. 2006. Inhibition of hepatitis C IRES-mediated gene expression by small hairpin RNAs in human hepatocytes and mice. Ann. N. Y. Acad. Sci. 1082:52-55. http://dx.doi.org/10.1196/annals.1348.060.
28. Dallas A, Ilves H, Ge Q, Kumar P, Shorenstein J, Kazakov SA, Cuellar TL, McManus MT, Behlke MA, Johnston BH. 2012. Right-and left-loop short shRNAs have distinct and unusual mechanisms of gene silencing. Nucleic Acids Res. 40:9255-9271. http://dx.doi.org/10.1093/nar/gks662.
29. Dallas A, Ilves H, Shorenstein J, Judge A, Spitler R, Contag C, Wong SP, Harbottle RP, Maclachlan I, Johnston BH. 2013. Minimal-length synthetic shRNAs formulated with lipid nanoparticles are potent inhibitors of hepatitis C virus IRES-linked gene expression in mice. Mol. Ther. Nucleic Acids 2:e123. http://dx.doi.org/10.1038/mtna.2013.50.
30. Kolli S, Wong SP, Harbottle R, Johnston B, Thanou M, Miller AD. 2013. pH-triggered nanoparticle mediated delivery of siRNA to liver cells in vitro and in vivo. Bioconjug. Chem. 24:314-332. http://dx.doi.org/10.1021/bc3004099.
31. Jeffs LB, Palmer LR, Ambegia EG, Giesbrecht C, Ewanick S, MacLachlan I. 2005. A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharm. Res. 22:362-372. http://dx.doi.org/10.1007/s11095-004-1873-z.
32. Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, Sah DW, Stebbing D, Crosley EJ, Yaworski E, Hafez IM, Dorkin JR, Qin J, Lam K, Rajeev KG, Wong KF, Jeffs LB, Nechev L, Eisenhardt ML, Jayaraman M, Kazem M, Maier MA, Srinivasulu M, Weinstein MJ, Chen Q, Alvarez R, Barros SA, De S, Klimuk SK, Borland T, Kosovrasti V, Cantley WL, Tam YK, Manoharan M, Ciufolini MA, Tracy MA, de Fougerolles A, MacLachlan I, Cullis PR, Madden TD, Hope MJ. 2010. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28:172-176. http://dx.doi.org/10.1038/nbt.1602.
33. Kamiya N, Iwao E, Hiraga N, Tsuge M, Imamura M, Takahashi S, Miyoshi S, Tateno C, Yoshizato K, Chayama K. 2010. Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor. J. Gen. Virol. 91:1668-1677. http://dx.doi.org/10.1099/vir.0.019315-0.
34. Kuiken C, Simmonds P. 2009. Nomenclature and numbering of the hepatitis C virus. Methods Mol. Biol. 510:33-53. http://dx.doi.org/10.1007/978-1-59745-394-3_4.
35. Castro C, Arnold JJ, Cameron CE. 2005. Incorporation fidelity of the viral RNA-dependent RNA polymerase: a kinetic, thermodynamic and structural perspective. Virus Res. 107:141-149. http://dx.doi.org/10.1016/j.virusres.2004.11.004.
36. Sullivan JC, De Meyer S, Bartels DJ, Dierynck I, Zhang EZ, Spanks J, Tigges AM, Ghys A, Dorrian J, Adda N, Martin EC, Beumont M, Jacobson IM, Sherman KE, Zeuzem S, Picchio G, Kieffer TL. 2013. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin. Infect. Dis. 57:221-229. http://dx.doi.org/10.1093/cid/cit226.
37. Shi N, Hiraga N, Imamura M, Hayes CN, Zhang Y, Kosaka K, Okazaki A, Murakami E, Tsuge M, Abe H, Aikata H, Takahashi S, Ochi H, Tateno-Mukaidani C, Yoshizato K, Matsui H, Kanai A, Inaba T, McPhee F, Gao M, Chayama K. 2013. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. Gut 62:1055-1061. http://dx.doi.org/10.1136/gutjnl-2012-302600.
38. Bukh J, Purcell RH, Miller RH. 1994. Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc. Natl. Acad. Sci. U. S. A. 91:8239-8243. http://dx.doi.org/10.1073/pnas.91.17.8239.
39. Santolini E, Migliaccio G, La Monica N. 1994. Biosynthesis and biochemical properties of the hepatitis C virus core protein. J. Virol. 68:3631-3641.
40. Honda M, Ping LH, Rijnbrand RC, Amphlett E, Clarke B, Rowlands D, Lemon SM. 1996. Structural requirements for initiation of translation by internal ribosome entry within genome-length hepatitis C virus RNA. Virology 222:31-42. http://dx.doi.org/10.1006/viro.1996.0395.
41. Lu HH, Wimmer E. 1996. Poliovirus chimeras replicating under the translational control of genetic elements of hepatitis C virus reveal unusual properties of the internal ribosomal entry site of hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 93:1412-1417. http://dx.doi.org/10.1073/pnas.93.4.1412.
42. Reynolds JE, Kaminski A, Kettinen HJ, Grace K, Clarke BE, Carroll AR, Rowlands DJ, Jackson RJ. 1995. Unique features of internal initiation of hepatitis C virus RNA translation. EMBO J. 14:6010-6020.
43. Wang TH, Rijnbrand RC, Lemon SM. 2000. Core protein-coding sequence, but not core protein, modulates the efficiency of cap-independent translation directed by the internal ribosome entry site of hepatitisCvirus. J. Virol. 74:11347-11358. http://dx.doi.org/10.1128/JVI.74.23.11347-11358.2000.
44. Alsaleh K, Delavalle PY, Pillez A, Duverlie G, Descamps V, Rouille Y, Dubuisson J, Wychowski C. 2010. Identification of basic amino acids at the N-terminal end of the core protein that are crucial for hepatitis C virus infectivity. J. Virol. 84:12515-12528. http://dx.doi.org/10.1128/JVI.01393-10.
45. Kim JH, Paek KY, Ha SH, Cho S, Choi K, Kim CS, Ryu SH, Jang SK. 2004. A cellular RNA-binding protein enhances internal ribosomal entry site-dependent translation through an interaction downstream of the hep-atitis C virus polyprotein initiation codon. Mol. Cell. Biol. 24:7878-7890. http://dx.doi.org/10.1128/MCB.24.18.7878-7890.2004.
46. Park SM, Paek KY, Hong KY, Jang CJ, Cho S, Park JH, Kim JH, Jan E, Jang SK. 2011. Translation-competent 48S complex formation on HCV IRES requires the RNA-binding protein NSAP1. Nucleic Acids Res. 39: 7791-7802. http://dx.doi.org/10.1093/nar/gkr509.
47. Honda M, Brown EA, Lemon SM. 1996. Stability of a stem-loop involving the initiator AUG controls the efficiency of internal initiation of translation on hepatitis C virus RNA. RNA 2:955-968.
48. Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, Tigges AM, Adiwijaya BS, Lin C, Kwong AD, Kieffer TL. 2008. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J. Infect. Dis. 198:800-807. http://dx.doi.org/10.1086/591141.
49. Le Pogam S, Seshaadri A, Kosaka A, Chiu S, Kang H, Hu S, Rajyaguru S, Symons J, Cammack N, Najera I. 2008. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J. Antimicrob. Chemother. 61:1205-1216. http://dx.doi.org/10.1093/jac/dkn085.
50. Adiwijaya BS, Herrmann E, Hare B, Kieffer T, Lin C, Kwong AD, Garg V, Randle JC, Sarrazin C, Zeuzem S, Caron PR. 2010. A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLoS Comput. Biol. 6:e1000745. http://dx.doi.org/10.1371/journal.pcbi.1000745.
51. Robbins M, Judge A, Ambegia E, Choi C, Yaworski E, Palmer L, McClintock K, MacLachlan I. 2008. Misinterpreting the therapeutic effects of small interferingRNAcaused by immune stimulation. Hum. Gene Ther. 19:991-999. http://dx.doi.org/10.1089/hum.2008.131.
52. Robbins M, Judge A, MacLachlan I. 2009. siRNA and innate immunity. Oligonucleotides 19:89-102. http://dx.doi.org/10.1089/oli.2009.0180.
53. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougerolles A, Endres S, Hartmann G. 2005. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11:263-270. http://dx.doi.org/10.1038/nm1191.
54. Sioud M. 2005. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequencedependent and requires endosomal localization. J. Mol. Biol. 348:1079-1090. http://dx.doi.org/10.1016/j.jmb.2005.03.013.
55. Judge A, MacLachlan I. 2008. Overcoming the innate immune response to small interfering RNA. Hum. Gene Ther. 19:111-124. http://dx.doi.org/10.1089/hum.2007.179.
56. Judge AD, Robbins M, Tavakoli I, Levi J, Hu L, Fronda A, Ambegia E, McClintock K, MacLachlan I. 2009. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J. Clin. Investig. 119:661-673. http://dx.doi.org/10.1172/JCI37515.
57. Berkhout B, Das AT. 2012. HIV-1 escape from rnai antivirals: yet another Houdini action? Mol. Ther. Nucleic Acids 1:e26. http://dx.doi.org/10.1038/mtna.2012.22.
58. Boden D, Pusch O, Lee F, Tucker L, Ramratnam B. 2003. Human immunodeficiency virus type 1 escape from RNA interference. J. Virol. 77:11531-11535. http://dx.doi.org/10.1128/JVI.77.21.11531-11535.2003.
59. Das AT, Brummelkamp TR, Westerhout EM, Vink M, Madiredjo M, Bernards R, Berkhout B. 2004. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J. Virol. 78:2601-2605. http://dx.doi.org/10.1128/JVI.78.5.2601-2605.2004.
60. Lavender H, Brady K, Burden F, Delpuech-Adams O, Denise H, Palmer A, Perkins H, Savic B, Scott S, Smith-Burchnell C, Troke P, Wright JF, Suhy D, Corbau R. 2012. In vitro characterization of the activity of PF-05095808, a novel biological agent for hepatitis C virus therapy. Antimicrob. Agents Chemother. 56:1364-1375. http://dx.doi.org/10.1128/AAC.05357-11.
61. Nevot M, Martrus G, Clotet B, Martinez MA. 2011. RNA interference as a tool for exploring HIV-1 robustness. J. Mol. Biol. 413:84-96. http://dx.doi.org/10.1016/j.jmb.2011.08.035.
62. Shah PS, Pham NP, Schaffer DV. 2012. HIV develops indirect crossresistance to combinatorial RNAi targeting two distinct and spatially distant sites. Mol. Ther. 20:840-848. http://dx.doi.org/10.1038/mt.2012.3.
63. Shah PS, Schaffer DV. 2012. Response to "HIV escape from RNAi antivirals: yet another Houdini action?" Mol. Ther. Nucleic Acids 1:e28. http://dx.doi.org/10.1038/mtna.2012.23.
64. von Eije KJ, ter Brake O, Berkhout B. 2008. Human immunodeficiency virus type 1 escape is restricted when conserved genome sequences are targeted byRNAinterference. J. Virol. 82:2895-2903. http://dx.doi.org/10.1128/JVI.02035-07.
65. Wilson JA, Richardson CD. 2005. Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region. J. Virol. 79:7050-7058. http://dx.doi.org/10.1128/JVI.79.11.7050-7058.2005.
66. Grimm D, Kay MA. 2007. Combinatorial RNAi: a winning strategy for the race against evolving targets? Mol. Ther. 15:878-888.
67. Gitlin L, Stone JK, Andino R. 2005. Poliovirus escape from RNA interference: short interfering RNA-target recognition and implications for therapeutic approaches. J. Virol. 79:1027-1035. http://dx.doi.org/10.1128/JVI.79.2.1027-1035.2005.
68. Kusov Y, Kanda T, Palmenberg A, Sgro JY, Gauss-Muller V. 2006. Silencing of hepatitis A virus infection by small interfering RNAs. J. Virol. 80:5599-5610. http://dx.doi.org/10.1128/JVI.01773-05.
69. Novobrantseva TI, Borodovsky A, Wong J, Klebanov B, Zafari M, Yucius K, Querbes W, Ge P, Ruda VM, Milstein S, Speciner L, Duncan R, Barros S, Basha G, Cullis P, Akinc A, Donahoe JS, Narayanannair Jayaprakash K, Jayaraman M, Bogorad RL, Love K, Whitehead K, Levins C, Manoharan M, Swirski FK, Weissleder R, Langer R, Anderson DG, de Fougerolles A, Nahrendorf M, Koteliansky V. 2012. Systemic RNAi-mediated gene silencing in nonhuman primate and rodent myeloid cells. Mol. Ther. Nucleic Acids 1:e4. http://dx.doi.org/10.1038/mtna.2011.3.